Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
ZUG, Switzerland, Feb. 5, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will webcast a live fireside chat, featuring Thomas Meyer, Chairman and CEO, at the 2016 Leerink Global Healthcare Conference on Thursday, February 11, 2015, at 8:30 a.m. EST from the Waldorf Astoria Hotel in New York. The webcast will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Auris Medical Leerink Conference Presentation http://hugin.info/160190/R/1984071/727288.pdf
HUG#1984071
CONTACTS: Auris Medical contacts:
Company: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94,
[email protected]
Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685,
[email protected]
